119 citations
,
June 2005 in “Journal of Molecular and Cellular Cardiology” This article reviews the therapeutic potential of potassium channel openers for various conditions related to metabolic distress but does not report new clinical results; it emphasizes the need for further research.
18 citations
,
October 2020 in “Journal of Pharmacology and Experimental Therapeutics” In isolated rat lymph vessels, this study found that ATP-sensitive potassium channel openers impair lymph contractions and reduce lymph flow, potentially contributing to peripheral edema.
13 citations
,
June 2023 in “Frontiers in Molecular Neuroscience” This review suggests that blocking the ATP-sensitive potassium (K ATP) channel, particularly the Kir6.1/SUR2B subtype, may prove effective in treating migraines, with preclinical data supporting this approach; however, human studies are absent, and potential side effects could complicate clinical use.
3 citations
,
April 2023 in “Frontiers in Pharmacology” This study identified high expression of the Sur2A subunit in cancerous cells in two animal models, highlighting a potential drug target in breast and renal cancers, with additional pharmacovigilance data linking KATP channel genes to varied cancer risks.
1 citations
,
January 2019 in “Advances in Medical Sciences” This study found that a combination of azelaic acid, minoxidil, and caffeine significantly reduced skin flap necrosis in rats, likely by increasing nitric oxide content and iNOS expression, compared to individual treatments.